{"task_id": "ad3a62710aa6c657", "source": "Approach to Internal Medicine_ A Resource Book for Clinical Practice ( PDFDrive ).pdf (Part 219/464)", "text": "atives\nPATHOPHYSIOLOGY (CONT\u2019D)\n208\nBladder Cancer\n\n--- Page 230 ---\n\u0002\nDISEASES (usually squamous cell carcinoma)\nschistosomiasis, chronic bladder infection, Balkan\nendemic nephropathy\nCLINICAL FEATURES\nLOCOREGIONAL\npainless intermittent hematuria\n(80%), bladder irritability (25%, hesitancy, urgency,\nfrequency, and dysuria), abdominal mass, suprapubic\nor flank pain, lymphedema\nMETASTATIC\ndyspnea, bone pain, jaundice\nCONSTITUTIONAL\nweight loss, anorexia, fatigue\nPARANEOPLASTIC\nhypercalcemia, systemic fibri\nnolysis, neuromuscular syndromes\nTNM STAGING\nTNM STAGING\nT stage\n\u0002 Ta=non invasive papillary carcinoma\n\u0002 Tis=carcinoma in situ (CIS), flat tumor\n\u0002 T1=invades lamina propria\n\u0002 T2=invades detrusor muscle (T2a=invades inner\nhalf superficial muscle, T2b=invades outer half\ndeep muscle)\n\u0002 T3=invades perivesical tissue (T3a=microscopic,\nT3b=macroscopic)\n\u0002 T4=invades surrounding tissue (T4a=prostate,\nuterus, vagina, T4b=pelvic wall, abdominal wall)\nN stage\n\u0002 N1=single LN, \u00042 cm\n\u0002 N2=single LN 2 5 cm, or multiple LN \u00045 cm\n\u0002 N3=any LN >5 cm\nM stage (bone, liver, lungs)\n\u0002 M1=distant metastasis\nSTAGE GROUPINGS\nStage TNM @=any\n5 year survival\n0a\n0is\nTaN0M0g\nTisN0M0\n>90%\nI\nT1N0M0\n85%\nII\nT2a bN0M0\n60%\nIII\nT3a bN0M0, T4aN0M0\n35%\nIV\nT4bN0M0, T@N1 3M0\nT@N@M1\n15%\nINVESTIGATIONS\nBASIC\n\u0002\nLABS\nCBCD, lytes, urea, Cr, AST, ALT, ALP, bilir\nubin, INR, PTT, albumin\n\u0002\nIMAGING\nIVP or triphasic CT abd/pelvis\n\u0002\nURINE CYTOLOGY\nsens 70%\n\u0002\nCYSTOSCOPY WITH BIOPSY\nPROGNOSTIC ISSUES\nRISK FACTORS FOR RECURRENCE OF SUPER\nFICIAL BLADDER TUMOR POST RESECTION\nprevious\nrecurrence,\nlarge\nsize,\nhigh,\ngrade,\nadvanced stage (T1 >Tis >Ta) multiple tumors,\ndiffuse CIS\nADVERSE PROGNOSTIC FACTORS\nsquamous cell\ncarcinoma or adenocarcinoma, invasion of muscle,\nlymphatics, or perivesical fat\nMANAGEMENT\nSUPERFICIAL\n\u0002\nSTAGE 0A, 0IS, I\ntransurethral resection (TUR)\n\u0006 fulguration \u0006 intravesicular therapy (BCG\u00036\n[bacillus Calmette Guerin], mitomycin C, thiotepa,\ndoxorubicin, epirubicin, Epodyl) \u0006 intravesicular\ninterferon. Radical cystectomy may be done if\nmultifocal CIS\nINVASIVE\n\u0002\nSTAGE II, STAGE III\nradical cystectomy \u0006 pel\nvic lymph node dissection or curative radia\ntion, (neo)adjuvant chemotherapy (gemcita\nbine cisplatin [GC], methotrexate vinblastine\ndoxorubicin cisplatin [MVAC], cisplatin metho\ntrexate vinblastine [CMV])\n\u0002\nSTAGE IV\npalliative chemotherapy (GC, MVAC,\nCMV)\nPATHOPHYSIOLOGY (CONT\u2019D)\nBladder Cancer\n209", "text_length": 2405, "metadata": {"source": "Approach to Internal Medicine_ A Resource Book for Clinical Practice ( PDFDrive ).pdf (Part 219/464)", "type": "chunk", "chunk_index": 218, "total_chunks": 464, "uploaded_by": "admin@admin.com", "upload_date": "2025-12-11T18:40:09.547915", "document_uuid": "fda2cab4-cdd9-4015-af24-46fd62c86d94", "filename": "Approach to Internal Medicine_ A Resource Book for Clinical Practice ( PDFDrive ).pdf", "category": "medical_pdf", "section": "body", "year": null, "outdated": false, "document_id": "fda2cab4-cdd9-4015-af24-46fd62c86d94"}, "created_at": "2025-12-11T18:40:09.548687", "status": "complete", "chunks_added": 2}